Previous Close | 11.80 |
Open | 11.80 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 11.80 - 11.80 |
52 Week Range | 9.80 - 11.80 |
Volume | |
Avg. Volume | 0 |
Market Cap | 92.279M |
Beta (5Y Monthly) | 1.26 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.39 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ADOCY
LYON, France, July 20, 2022--Regulatory News: Under the liquidity agreement entrusted by ADOCIA (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account on June 30th, 2022:
LYON, France, July 11, 2022--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovati
LYON, France, June 23, 2022--Regulatory News: Adocia (Euronext Paris : FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the publication of the Letter to Shareholders for the 1st semester of 2022.